Prof Martine Piccart talks to ecancer about heterogeneity of breast cancer tumours, advancements in technology and the future of treating breast cancer at IMPAKT 2012 in Brussels, May 2012.
IMPAKT 2012 focused on the latest developments in translational research, teaching young oncologists on how to treat patients in the coming years and especially on the heterogeneity of tumours.
New technologies hold the potential for understanding the evolution of breast cancer and the differences between primary tumours and metastases.
With HER tumours, each type of tumour, slow growing and highly proliferating, hold very specific molecular characteristics that can potentially unlock new understandings of the disease through the patient's immune system and the microenvironment.
Filming Supported by Amgen